Bellus Health
BioTech/Drugs - Laval, QC, CA
Bellus Health Senior Management
Bellus Health Details
BELLUS Health is a clinical stage biotechnology company developing novel therapeutics for the treatment of chronic cough and other chronic disorders triggered by hypersensitization. The Company's lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of chronic cough and chronic pruritus. P2X3 receptors are channels expressed in sensory nerves throughout the body and play an important role in the sensitization of the nervous system to various stimuli. BELLUS is exploring how P2X3 activation contributes to irritation and pain, and whether inhibition of P2X3 receptors can help treat other afferent hypersensitization-related disorders. BELLUS Health is based in Laval, Quebec and its shares trade under the ticker BLU on both Nasdaq and the Toronto Stock Exchange.
Bellus Health Technologies
Email Providers
Outlook
Load Balancers
Apache
CMS
WordPress.org
Fonts
Google Font API
Other
Microsoft Office 365
Search Marketing
Adobe Marketing Cloud